Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie · 2025
Carnosol and melatonin co-treatment attenuates neuroinflammation and oxidative stress in experimental autoimmune encephalomyelitis.
СтатьяНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Azimzadeh Maryam, Jafarinia Morteza
Аннотация
INTRODUCTION: Neurodegenerative diseases such as multiple sclerosis (MS) involve neuronal loss and functional impairment driven by inflammation and oxidative stress. Carnosol and melatonin are recognized for their anti-oxidative properties and potential to support remyelination. This study assessed the combined therapeutic effect of Carnosol and melatonin in the experimental autoimmune encephalomyelitis (EAE) model.
MATERIALS AND METHODS: EAE was induced in 28 female C57BL/6 mice, which were divided into four groups: Control, Carnosol (50 mg/kg), melatonin (10 mg/kg), and combination treatment. From day 9 post-immunization (DPI), clinical signs were scored daily. On day 30, spinal cord, liver, and spleen samples were collected. Histological and immunofluorescence staining evaluated inflammation and remyelination. Serum oxidative markers, malondialdehyde (MDA), PC, and 8-hydroxy-2'-deoxyguanosine (8-OHdG), were measured by enzyme-linked immunosorbent assay (ELISA). Gene expression of nuclear factor erythroid 2-related factor 2 (Nrf2), nuclear factor-kappa B (NF-κB), interleukin (IL)-10, IL-17, Heme oxygenase 1 (HO-1), and NAD(P)H quinone dehydrogenase 1 (NQO1) was analyzed by real-time reverse transcription polymerase chain reaction (RT-PCR).
RESULTS: Co-treatment with Carnosol and melatonin markedly improved clinical scores, reduced central nervous system (CNS) inflammation, and increased remyelination. Serum levels of MDA, PC, and 8-OHdG were significantly lowered. Spinal cord analysis revealed upregulated Nrf2 and downregulated NF-κB. Spleen samples showed elevated IL-10 and reduced IL-17. In the liver, HO-1 and NQO1 expression were highest in the combination group.
CONCLUSION: Combined Carnosol and melatonin treatment demonstrates compelling potential to counteract inflammation and oxidative stress while promoting remyelination, supporting its further investigation as a therapeutic strategy for MS.
MATERIALS AND METHODS: EAE was induced in 28 female C57BL/6 mice, which were divided into four groups: Control, Carnosol (50 mg/kg), melatonin (10 mg/kg), and combination treatment. From day 9 post-immunization (DPI), clinical signs were scored daily. On day 30, spinal cord, liver, and spleen samples were collected. Histological and immunofluorescence staining evaluated inflammation and remyelination. Serum oxidative markers, malondialdehyde (MDA), PC, and 8-hydroxy-2'-deoxyguanosine (8-OHdG), were measured by enzyme-linked immunosorbent assay (ELISA). Gene expression of nuclear factor erythroid 2-related factor 2 (Nrf2), nuclear factor-kappa B (NF-κB), interleukin (IL)-10, IL-17, Heme oxygenase 1 (HO-1), and NAD(P)H quinone dehydrogenase 1 (NQO1) was analyzed by real-time reverse transcription polymerase chain reaction (RT-PCR).
RESULTS: Co-treatment with Carnosol and melatonin markedly improved clinical scores, reduced central nervous system (CNS) inflammation, and increased remyelination. Serum levels of MDA, PC, and 8-OHdG were significantly lowered. Spinal cord analysis revealed upregulated Nrf2 and downregulated NF-κB. Spleen samples showed elevated IL-10 and reduced IL-17. In the liver, HO-1 and NQO1 expression were highest in the combination group.
CONCLUSION: Combined Carnosol and melatonin treatment demonstrates compelling potential to counteract inflammation and oxidative stress while promoting remyelination, supporting its further investigation as a therapeutic strategy for MS.